Since the first successful allogeneic hematopoietic SCT (HSCT) was performed in Korea in 1983, there has been a noticeable progress in both the quantity and quality of HSCT over 24 years. There are 38 HSCT centers in Korea and the number of both allogeneic and autologous HSCTs has been increasing every year. As of December 2006, a total of 9561 HSCTs have been carried out in Korea, including 5617 allogeneic (59%) and 3944 autologous HSCTs (41%). The main indications were acute leukemia (3979, 78% allogeneic); lymphoma (1244, 90% autologous); myeloma (939, 92% autologous) and aplastic anemia (938). Characteristically, severe aplastic anemia accounts for a considerable proportion of transplants (10%), compared with western countries. Recently, there has been a marked increase in the number of unrelated transplants and the usage of PBSCs. The pattern of infectious diseases associated with HSCT is quite different. The rapid expansion of unrelated donor pools worldwide has changed the outlook of an unrelated donor search in Korea.
search Hematopoietic SCT (HSCT) has become the standard treatment for many patients with congenital or acquired disorders of the hematopoietic system or with chemosensitive, radiosensitive or immunosensitive malignancies. [1] [2] [3] Its introduction to clinical medicine dates back to 1968, with the first reports of successful BM transplants from HLA-identical siblings for patients with immune deficiency disorders. 4 HSCT has seen a rapid expansion and a constant evolution in technology use. Stem cell sources have extended from BM to PBPC and cord blood, and donor type from HLA-matched sibling to unrelated donor and haploidentical donor. Ever since the Catholic Hematopoietic Stem Cell Transplantation Center (CHSCTC) successfully performed the first case of allogeneic HSCT for a patient with ALL in Korea in 1983, 5 there has been progress in both the quantity and quality of HSCT over 24 years. This review describes the current status of HSCT activity in Korea.
Numbers of HSCT
Since 1983, a total of 9561 cases of HSCT have been performed in Korea until December 2006 (Figure 1 ), which consisted of 5617 (59%) cases with allogeneic and 3944 (41%) cases with autologous HSCT. The annual number of both allogeneic and autologous HSCT has been increased every year (Figure 2 ). In 2006, of the total 1314 transplants, 694 (53%) allogeneic and 620 (47%) autologous HSCTs were carried out. CHSCTC had carried out 2863 cases of HSCT until December 2006, which was 30% of the total HSCT cases in Korea.
HSCT centers
There are 38 HSCT centers in Korea and the total number of transplants performed per year has been increasing ( Figure 2 ). Of the total 1314 transplants in 2006, 832 (63%) transplants were performed in 4 of 38 centers, and 256 (19.5%) transplants were carried out in CHSCTC.
Donor type
Of the 5617 allogeneic transplants, HLA-identical siblings were used as donors for 3827 (68%) recipients and an unrelated volunteer donor for 1477 (26%), and cord blood for 313 (6%) (Figure 1) . Recently, there has been a marked increase in unrelated transplants. Of the total 694 allogeneic transplants in 2006, the proportion of unrelated transplants (355 cases, 51%) was higher than sibling transplants (339, 49%) ( Figure 2 ). This trend is consistent with a worldwide phenomenon of the increasing use of unrelated donors. 6 
Disease indications
Indications for HSCT between 1983 and 2006 are listed in Figure 3a . The main indications were acute leukemia, being present in 3979 patients (42%), allogeneic HSCT (3089 patients, 78%), autologous HSCT (890, 22%); lymphoproliferative disorders (1244, 13%), allogeneic HSCT (123, 10%), autologous HSCT (1121, 90%); multiple myeloma (939, 10%), allogeneic HSCT (78, 8%) and autologous HSCT (861, 92%). Characteristically, allogeneic HSCT for 938 patients with severe aplastic anemia (10%) has been performed in Korea, which accounts for a considerable proportion, when compared with Western countries. 6, 7 Indications for HSCT in 2006 are listed in Figure 3b . The main indications were acute leukemia, being present in 526 patients (40%), allogeneic HSCT (455 patients, 86%), autologous HSCT (71, 14%); multiple myeloma (222, 17%), allogeneic HSCT (13, 6%), autologous HSCT (209, 94%); lymphoproliferative disorders (186, 14%), allogeneic HSCT (16, 9%), autologous HSCT (170, 91%) and severe aplastic anemia (99, 7.5%). There were trends of a reduction in HSCT for CML due to the successful adoption of targeted therapy and an increase in HSCT for myeloma, which might be affected by the increased number of planned tandem transplants.
Stem cell source
Of the total 9561 cases, the stem cell source of HSCT consisted of 4203 (44%) cases with BM, 4809 (50%) with PBPC, 233 (2.4%) with combined BM and PBPC, 313 (3%) with cord blood, and 3 with combined cord blood and PBPC.
In 2006, there has been an increase in using PBPC as a stem cell source, which was consistent with the data of other registries. 6, 7 Of the 1314 cases, PBPC (935 cases, 71%) was used most frequently as a stem cell source, 286 (22%) cases with BM, 77 (6%) cases with cord blood and 16 (1.2%) cases in which combined BM and PBPC were used.
Special observation regarding transplantation
One of the distinguishing features associated with complications after allogeneic HSCT is the relatively lower incidence of acute GVHD in Korea. The incidence of acute GVHD over grade II was 141 (32%) out of 437 adult patients who underwent allogeneic HSCT at two centers in Korea between January 1996 and January 2004. white Americans, 9 the relatively lower incidence of acute GVHD in Korea might also be partly explained by the fact that Korea is a genetically homogeneous community.
Infectious disease issues related to transplantation
According to CHSCTC's data, 10, 11 during the pre-engraftment period, bacterial infection was predominant. After engraftment, viral infection was predominant. Among the fungal infections, mold forms constituted the majority of pathogens. The incidence of invasive fungal infection showed bimodal distribution with peak correlated with neutropenia and GVHD. In the late-recovery phase, viral and fungal diseases were the major opportunistic infections.
Although the prevalence of tuberculosis has dramatically decreased nowadays, Korea is still a tuberculosis-endemic country. The incidence of active tuberculosis after allogeneic HSCT from one center was reported to be 3.1%, 12 which was similar to the CHSCTC result (3.0%), 10 which is 10-fold higher than that of the general population.
High CMV seropositivity is another characteristic of the Korean population. Thus, reactivation rather than new or repeated infection should be considered at first when CMV infection develops in Korea. Owing to this high prevalence of CMV seropositivity, preemptive therapy for CMV disease after allogeneic HSCT is very important to decrease the mortality and morbidity associated with CMV, especially in Korea. CHSCTC data showed a good result of risk-adapted preemptive therapy for CMV disease with ganciclovir. 13 
Coordination process for unrelated HSCT in Korea
There are two registries in Korea for the recruitment of volunteer donors, maintaining and matching HLA information of them, which are the Korea Marrow Donor Program and the Catholic Hemopoietic Stem Cell Bank. HLA-matching rate (serotyping) is 72%. It takes 3-12 months to confirm the donor's intention and the actual donation rate is 50-80%. After the confirmation of donation, donor's HLA (genotyping) and the presence of infectious diseases are rechecked. The two registries covered 83% of unrelated HSCT in Korea. Recently, the rapid expansion of unrelated donor pools worldwide has changed the outlook of an unrelated donor search in Korea. If there are no donors in Korea, donor information from international registries including Japan Marrow Donor Program, Buddhist Tzu Chi Stem Cells Center, National Marrow Donor Program and Zentrales Knochenmarkspender-Register Deutschland has been used for searching matched unrelated donors. Of 1477 cases with unrelated HSCT, 250 (17%) cases found donors through the above international registries (Figure 4 ).
Future considerations
The National Medical Insurance System (NMIS) in Korea started to cover HSCT to the age of 50 years with less advanced disease in October 1992. The coverage for autologous HSCT to the age of 65 years was extended in November 1997 and allogeneic HSCT to the age of 65 years in October 2005. However, the decision for HSCT is still being affected by an insurance problem, because NMIS could not cover the full indications of HSCT. In addition, the increased costs for the donor search and costs for the transplant harvest and transfer add substantially to overall transplant costs in unrelated HSCT. Donors within a country might be the only possible choice for transplant physicians for some patients. As reported in the European Group for Blood and Marrow Transplantation Survey 2005, the gap in transplant rates of unrelated HSCT between countries with high or middle income will likely increase in the future. 6 Despite these obstacles, it is expected to increase the number of HSCTs annually owing to the substantial extended coverage of NMIS and efforts of all workers associated with the transplant process, including physicians, nurses, coordinators and public service personnel in Korea. 
